EGFR and non-small cell lung carcinoma: In a multicohort open-labeled phase I trial (CHRYSALIS) in patients with metastatic NSCLC, amivantamab was investigated in different molecular-defined subgroups, including patients with EGFR exon 20 insertion mutation, METex14 mutation, and METamp.